News on lab-developed tests and emerging diagnostic technologies.
The drug, tepotinib, will now be available to treat advanced non-small cell lung cancer patients in Japan with MET exon 15 skipping alterations.
The companies will work together to develop a next-generation sequencing-based companion diagnostic for an undisclosed cancer therapy.
Health systems' molecular testing labs haven't had to cut back on genomic profiling for cancer patients yet but may need to accommodate COVID-19 testing if needed.
SkylineDx said that the firms will work together to develop predictive immunological signatures for BioInvent's lead therapy candidate.
Radboud University Medical Center researchers developed and validated the single-molecule molecular inversion probe-centered workflow for more efficient BRCA1/2 testing.
